Journey Medical (US:DERM) Globenewswire·2025-06-20 12:30Core Viewpoint - Emrosi™ has demonstrated efficacy in treating moderate-to-severe papulopustular rosacea, independent of body weight differences, supporting its FDA approval in November 2024 [1][6][8] Group 1: Clinical Trial Results - Data from two Phase 3 trials (MVOR-1 and MVOR-2) showed that Emrosi can be prescribed without regard to body weight, reducing potential dosing errors [2][5] - In MVOR-1, 75.5% of subjects with body weight ≤ median achieved IGA treatment success with Emrosi compared to 51.0% with doxycycline and 28.2% with placebo [4] - In MVOR-2, 65.0% of subjects with body weight > median achieved IGA treatment success with Emrosi compared to 33.9% with doxycycline and 22.6% with placebo [4] Group 2: Efficacy and Safety - Emrosi showed superior efficacy on both co-primary endpoints compared to placebo and doxycycline, with no significant differences in adverse events reported [5][6] - The most common adverse reaction was dyspepsia, occurring in ≥1% of subjects treated with Emrosi [9] Group 3: Company Overview - Journey Medical Corporation focuses on marketing FDA-approved prescription products for dermatological conditions and currently markets eight such products [11] - The company is based in Scottsdale, Arizona, and was founded by Fortress Biotech, Inc. [11]